NeoGenomics is trading 4.41% higher at $19.17, with the move appearing primarily driven by healthcare-sector strength.
- Healthcare rose 1.27% on renewed biotechnology optimism, including favorable Goldman Sachs coverage and ongoing acquisition interest; elevated Treasury yields weighed on broader U.S. indexes.
- Shares reversed their September 23 decline. No company-specific announcement, earnings release, or analyst action was identified for September 24, 2026; the latest corporate item was participation in Morgan Stanley’s healthcare conference.